November 27, 2017
A team of University of California San Diego School of Medicine and Moores Cancer Center researchers studying new drugs designed to break resistance to cancer immunotherapy has been awarded a V Foundation for Cancer Research translational grant of $600,000 over three years.
May 13, 2021
…to UC San Diego’s Head and Neck Cancer Center Hanna and Mark Gleiberman have embraced philanthropic endeavors supporting UC San Diego and the San Diego community. Most recently, the couple has made a $12 million gift to support the newly named Hanna and Mark Gleiberman Head and Neck Cancer Center…
March 13, 2023
UC San Diego researchers have identified a strong association between the product of a gene expressed in most cancers and elevated levels of white blood cells that produce antibodies within tumors, suggesting a new therapeutic target.
November 14, 2022
Joseph A. Califano III, MD, has been named director of Moores Cancer Center at UC San Diego Health.
August 3, 2014
…recognized as being associated with more aggressive forms of cancer, researchers at the University of California, San Diego School of Medicine have found evidence suggesting that the deleterious health effects of the mutated gene may in large part be due to other genetic abnormalities, at least in squamous cell head…
August 4, 2022
…Vaccine After Advanced Throat Cancer It was a typical morning for Mike West, one that usually started with a quick shave before getting ready for work. However, this specific morning, he felt something unusual: a small, but hard lump just under his skin on his throat. West decided to call…
June 22, 2021
Longtime supporters of cancer research and patient care at Moores Cancer Center at UC San Diego Health have given University of California San Diego School of Medicine $2 million to establish the Iris and Matthew Strauss Chancellor’s Endowed Chair in Head and Neck Surgery.
December 10, 2020
…cells) to destroy his cancer. New Personalized Immunotherapy Trial Launched Despite COVID-19 Pandemic First patient to receive individualized TIL therapy undergoes treatment at Moores Cancer Center Since 2016, Bernard Thurman has undergone traditional treatments, experimental therapies and surgeries to counter the cancer within him, but nothing successfully eradicated the disease.…
September 21, 2017
Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers may have found a way to double down on immunotherapy’s effectiveness.
January 29, 2015
…has produced the most comprehensive integrative analysis yet of head and neck squamous cell carcinomas (HNSCCs), a particularly malignant and deadly type of tumor that accounts for roughly 3 percent of all cancers in the United States.
